Evidence map›Paper›PMID 33168053›Full record

ArticleMolecular neurodegeneration2020

Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model.

Sanjib Guha, Sarah Fischer, Gail V W Johnson, Keith Nehrke

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 60 citations in OpenAlex.

  1. Tau protein as a regulator of mitochondrial function and dynamics.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Modified tau leads to neuronal and global ribosome dysfunction inbioRxiv : the preprint server for biology · 2025
    Article
  6. Mitochondrial dysfunction in Alzheimer's disease: Guiding the path to targeted therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  7. Unraveling Molecular Targets for Neurodegenerative Diseases ThroughInternational journal of molecular sciences · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Towards Understanding Neurodegenerative Diseases: Insights fromInternational journal of molecular sciences · 2023
    Review
  15. Review
  16. Biomolecules · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sanjib GuhaDepartment of Anesthesiology & Perioperative Medicine, Box 604, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY, 14642, USA.
Sarah FischerDepartment of Medicine, Box 675, University of Rochester Medical Center, Nephrology Division, 601 Elmwood Avenue, Rochester, NY, 14642, USA.
Gail V W JohnsonDepartment of Anesthesiology & Perioperative Medicine, Box 604, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY, 14642, USA. Gail_Johnsonvoll@urmc.rochester.edu.
Keith NehrkeDepartment of Medicine, Box 675, University of Rochester Medical Center, Nephrology Division, 601 Elmwood Avenue, Rochester, NY, 14642, USA. Keith_Nehrke@urmc.rochester.edu.ORCID 0000-0001-9697-726X
University of Rochester Medical Center · US

Funding

Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Ann E. Rougvie · 2012 to 2026
$7.5M
Tau Post-Translational Modifications and Mitochondrial Quality ControlR01AG067617 · NIA · UNIVERSITY OF ROCHESTER · PI JOHNSON, GAIL V. W., NEHRKE, KEITH · 2020 to 2024
$2.9M
Tau protein turnover and mitochondrial stress responsesR21AG060627 · NIA · UNIVERSITY OF ROCHESTER · PI JOHNSON, GAIL V. W. · 2018 to 2019
$424k
NIA NIH HHS R01 AG067617NIA NIH HHS R21 AG060627NIH HHS P40 OD010440
6 · The paper itself

Abstract

backgroundA defining pathological hallmark of the progressive neurodegenerative disorder Alzheimer's disease (AD) is the accumulation of misfolded tau with abnormal post-translational modifications (PTMs). These include phosphorylation at Threonine 231 (T231) and acetylation at Lysine 274 (K274) and at Lysine 281 (K281). Although tau is recognized to play a central role in pathogenesis of AD, the precise mechanisms by which these abnormal PTMs contribute to the neural toxicity of tau is unclear.

methodsHuman 0N4R tau (wild type) was expressed in touch receptor neurons of the genetic model organism C. elegans through single-copy gene insertion. Defined mutations were then introduced into the single-copy tau transgene through CRISPR-Cas9 genome editing. These mutations included T231E, to mimic phosphorylation of a commonly observed pathological epitope, and K274/281Q, to mimic disease-associated lysine acetylation - collectively referred as "PTM-mimetics" - as well as a T231A phosphoablation mutant. Stereotypical touch response assays were used to assess behavioral defects in the transgenic strains as a function of age. Genetically-encoded fluorescent biosensors were expressed in touch neurons and used to measure neuronal morphology, mitochondrial morphology, mitophagy, and macro autophagy.

resultsUnlike existing tau overexpression models, C. elegans single-copy expression of tau did not elicit overt pathological phenotypes at baseline. However, strains expressing disease associated PTM-mimetics (T231E and K274/281Q) exhibited reduced touch sensation and neuronal morphological abnormalities that increased with age. In addition, the PTM-mimetic mutants lacked the ability to engage neuronal mitophagy in response to mitochondrial stress.

conclusionsLimiting the expression of tau results in a genetic model where modifications that mimic pathologic tauopathy-associated PTMs contribute to cryptic, stress-inducible phenotypes that evolve with age. These findings and their relationship to mitochondrial stress provides a new perspective into the pathogenic mechanisms underlying AD.

Indexed as

AnimalsAnimals, Genetically ModifiedCaenorhabditis elegansDisease Models, AnimalHumansMitophagyMutationNerve DegenerationTauopathiestau ProteinsMAPT protein, humantau ProteinsAlzheimer’s diseaseC. elegansNeurodegenerationPost-translational modificationsTau

Identifiers

PMID33168053
PMCPMC7654055
OpenAlexW3104455432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.